NOW APPROVED

Introducing the first and only FDA-approved treatment indicated for adults with tardive dyskinesia

Register for updates

Thank you for your interest in INGREZZA.

I am a:
Email is required, but please select other communication methods below:
(Data fees may apply.)
*Notes required field.
Email is required, but please select other communication methods below:
(Data fees may apply.)
*Notes required field.

Almost finished...

Thank you for submitting your information. Please check your email inbox to confirm your subscription. If you do not receive an email, please check your spam or junk folder, as the message may have been filtered.

We're sorry!

Only US healthcare professionals may register.